<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38813452</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2050-0904</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Clinical case reports</Title><ISOAbbreviation>Clin Case Rep</ISOAbbreviation></Journal><ArticleTitle>Long-COVID symptoms improved after MDMA and psilocybin therapy: A case report.</ArticleTitle><Pagination><StartPage>e8791</StartPage><MedlinePgn>e8791</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e8791</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/ccr3.8791</ELocationID><Abstract><AbstractText Label="KEY CLINICAL MESSAGE" NlmCategory="UNASSIGNED">Long-COVID syndrome lacks effective holistic treatment options. We present a case of a 41-year-old fully vaccinated female with Long-COVID syndrome who obtained significant symptomatic relief after self-medicating with psilocybin and MDMA.</AbstractText><AbstractText Label="ABSTRACT" NlmCategory="UNASSIGNED">Long-COVID, a syndrome persisting after the acute phase of coronavirus disease 2019 (COVID-19), lacks effective holistic treatment options. We present a case of a 41-year-old fully vaccinated female with Long-COVID syndrome who obtained significant symptomatic relief by self-prescribing psilocybin and MDMA. Future research is needed to assess safety and efficacy.</AbstractText><CopyrightInformation>&#xa9; 2024 The Authors. Clinical Case Reports published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chopra</LastName><ForeName>Harman</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Johns Hopkins School of Medicine Baltimore Maryland USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furnish</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University of California San Diego Health San Diego California USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verduzco-Gutierrez</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Texas San Antonio Health San Antonio Texas USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jevotovsky</LastName><ForeName>David S</ForeName><Initials>DS</Initials><Identifier Source="ORCID">0009-0004-0236-2600</Identifier><AffiliationInfo><Affiliation>New York University Grossman School of Medicine New York New York USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castellanos</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of California San Diego Health San Diego California USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Case Rep</MedlineTA><NlmUniqueID>101620385</NlmUniqueID><ISSNLinking>2050-0904</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID&#x2010;19</Keyword><Keyword MajorTopicYN="N">MDMA</Keyword><Keyword MajorTopicYN="N">case report</Keyword><Keyword MajorTopicYN="N">long&#x2010;COVID</Keyword><Keyword MajorTopicYN="N">neurotropics</Keyword><Keyword MajorTopicYN="N">psilocybin</Keyword></KeywordList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>30</Day><Hour>4</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38813452</ArticleId><ArticleId IdType="pmc">PMC11133386</ArticleId><ArticleId IdType="doi">10.1002/ccr3.8791</ArticleId><ArticleId IdType="pii">CCR38791</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Proal AD, VanElzakker MB. Long Covid or post&#x2010;acute sequelae of COVID&#x2010;19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021;12:698169. doi:10.3389/fmicb.2021.698169</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ. Long Covid or post&#x2010;covid&#x2010;19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis. 2021;53(10):737&#x2010;754. doi:10.1080/23744235.2021.1924397</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.1924397</ArticleId><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Argento E, Christie D, Mackay L, Callon C, Walsh Z. Psychedelic&#x2010;assisted psychotherapy after COVID&#x2010;19: the therapeutic uses of psilocybin and MDMA for pandemic&#x2010;related mental health problems. Front Psych. 2021;12:716593. doi:10.3389/fpsyt.2021.716593</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2021.716593</ArticleId><ArticleId IdType="pmc">PMC8450400</ArticleId><ArticleId IdType="pubmed">34552518</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurtz JS, Patel NA, Gendreau JL, et&#xa0;al. The use of psychedelics in the treatment of medical conditions: an analysis of currently registered psychedelics studies in the American drug trial registry. Cureus. 2022;14:e29167. doi:10.7759/cureus.29167</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.29167</ArticleId><ArticleId IdType="pmc">PMC9567237</ArticleId><ArticleId IdType="pubmed">36259015</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera JE, Niehaus WN, Whiteson J, et&#xa0;al. Multidisciplinary collaborative consensus guidance statement on the assessment and treatment of fatigue in postacute sequelae of SARS&#x2010;COV&#x2010;2 infection patients. PM R. 2021;13(9):1027&#x2010;1043. doi:10.1002/pmrj.12684</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmrj.12684</ArticleId><ArticleId IdType="pmc">PMC8441628</ArticleId><ArticleId IdType="pubmed">34346558</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2010;146. doi:10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Gattuso JJ, Perkins D, Ruffell S, et&#xa0;al. Default mode network modulation by psychedelics: a systematic review. Int J Neuropsychopharmacol. 2022;26(3):155&#x2010;188. doi:10.1093/ijnp/pyac074</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ijnp/pyac074</ArticleId><ArticleId IdType="pmc">PMC10032309</ArticleId><ArticleId IdType="pubmed">36272145</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapoor A, Mahajan G, Kapur A. State of brain networks in long covid: post mild to moderate acute COVID&#x2010;19 disease. SSRN Electron J. 2022;1&#x2010;26. doi:10.2139/ssrn.4309672</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.4309672</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin DA, Nichols CD. The effects of hallucinogens on gene expression. Behavioral neurobiology of psychedelic. Drugs. 2017;36:137&#x2010;158. doi:10.1007/7854_2017_479</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/7854_2017_479</ArticleId><ArticleId IdType="pubmed">28677095</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel JS, Daily JE, Perry DA, Nicol GE. Psychedelic drug legislative reform and legalization in the US. JAMA Psychiatry. 2023;80(1):77&#x2010;83. doi:10.1001/jamapsychiatry.2022.4101</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2022.4101</ArticleId><ArticleId IdType="pmc">PMC10069558</ArticleId><ArticleId IdType="pubmed">36477830</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug&#x2010;drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology. 2022;239(6):1945&#x2010;1976. doi:10.1007/s00213-022-06083-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-022-06083-y</ArticleId><ArticleId IdType="pmc">PMC9177763</ArticleId><ArticleId IdType="pubmed">35253070</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston CB, Mangini M, Grob C, Anderson B. The safety and efficacy of psychedelic&#x2010;assisted therapies for older adults: knowns and unknowns. Am J Geriatr Psychiatry. 2023;31(1):44&#x2010;53. doi:10.1016/j.jagp.2022.08.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jagp.2022.08.007</ArticleId><ArticleId IdType="pubmed">36184377</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Institute on Drug Abuse
. What are the effects of MDMA?
National Institutes of Health. 2017. Accessed February 19, 2024. https://nida.nih.gov/publications/research&#x2010;reports/mdma&#x2010;ecstasy&#x2010;abuse/what&#x2010;are&#x2010;effects&#x2010;mdma.</Citation></Reference><Reference><Citation>Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264&#x2010;355. doi:10.1124/pr.115.011478</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.115.011478</ArticleId><ArticleId IdType="pmc">PMC4813425</ArticleId><ArticleId IdType="pubmed">26841800</ArticleId></ArticleIdList></Reference><Reference><Citation>
Center for Drug Evaluation and Research
. U.S. Department of Health and Human Services Food and Drug Administration; 2023. Accessed February 18, 2024. https://www.fda.gov/media/169694/download.</Citation></Reference><Reference><Citation>Schindler EAD, Sewell RA, Gottschalk CH, et&#xa0;al. Exploratory controlled study of the migraine&#x2010;suppressing effects of psilocybin. Neurotherapeutics. 2021;18(1):534&#x2010;543. doi:10.1007/s13311-020-00962-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-020-00962-y</ArticleId><ArticleId IdType="pmc">PMC8116458</ArticleId><ArticleId IdType="pubmed">33184743</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler EA, Sewell RA, Gottschalk CH, et&#xa0;al. Exploratory investigation of a patient&#x2010;informed low&#x2010;dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double&#x2010;blind, placebo&#x2010;controlled trial. Headache. 2022;62(10):1383&#x2010;1394. doi:10.1111/head.14420</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/head.14420</ArticleId><ArticleId IdType="pubmed">36416492</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>